Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,

@inproceedings{Ritchlin2014EfficacyAS,
  title={Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,},
  author={Christopher T. Ritchlin and Proton Rahman and Arthur J Kavanaugh and Iain B. Mcinnes and Llu{\'i}s Puig and Shu Li and Yuhua Wang and Yaung-Kaung Shen and Mittie K Doyle and Alan M. Mendelsohn and Alice Bendix Gottlieb and Michelle Perate and Mary Whitman and Lisa T Dooley and Rieki Alten and Charles A Birbara and Erin E. Boh and J{\"u}rgen Braun and Jeremy Budd and C Chattapadhyay and Dariusz Chudzik and Pascal Claudepierre and R Cooper and Edit Drescher and Jan Peter Dutz and Christopher R. W. Edwards and B E Elewski and Hisham El-Kadi and Ludwig Erlacher and R N Flipo and SA Fretzin and Ene George and Geoffrey Gladstein and R. Griffin and MW Grisanti and Lynn Guenther and Wayne Gulliver and Kathryn Hobbs and E Huang and Elena Ilivanova and Slawomir Jeka and Majed M. Khraishi and M Kokhan and Neil J. Korman and Rod Kunynetz and C Leonardi and Christiane Lessard and Ulf Lindquist and Alan J. Hu Andrew K. Martin and RT Matheson and F. D. Murphy and Eugeniy L Nasonov and W Palmer and Katherine Papp and J{\"u}rgen Rech and Maria Rell-Bakalarska and Pheobe Rich and Colleen Rosen and A Rudin and A Ruppert-Roth and Clemens Scheinecker and Sandra Seigel and Soraya Shaikh and Tom Sheeran and WJ Shergy and EL Siegel and Stanislav Sierakowski and H Sofen and S{\'a}ndor Sz{\'a}nt{\'o} and Hasan Tahir and Eniko Telegdy and Dusan Toth and Dean Walker and Anthony Gerard Wilson and Matthias Witt and Juergen Wollenhaupt and D Zoschke and A Zubrzycka},
  booktitle={Annals of the rheumatic diseases},
  year={2014}
}
OBJECTIVE Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents. METHODS In this phase 3, multicentre, placebo-controlled trial, 312 adults with active PsA were randomised (stratified by site, weight (≤100 kg/>100 kg), methotrexate use) to ustekinumab 45 mg or 90 mg at week 0, week 4, q12 weeks or placebo at week 0, week… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 21 times over the past 90 days. VIEW TWEETS